ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.

GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca New York, USA, June 26, 2024 (GLOBE NEWSWIRE) -- GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns...

PatchMD Releases Medical Weight Loss Resources with Expert-Reviewed Articles on GLP-1 Agonists Las Vegas, NV, June 14, 2024 (GLOBE NEWSWIRE) -- PatchMD, a leader in innovative vitamin supplement delivery, is excited to announce the release of a series of comprehensive resources designed to...